Notes to the Financial Statements Note 9: Property, Plant and Equipment 14 K ey capital investments made during the year includes the CSL Melbourne Headquarters, a new cell-based influenza vaccine manufacturing facility in Tullamarine, Australia, continued investment in the Group’s R&D facilities including in Marburg, Germany and Waltham, United States and new plasma centres. Land US$m Buildings US$m Leasehold improvements US$m 2023 2022 2023 2022 2023 2022 Cost 65 36 2,284 1,819 666 597 Accumulated depreciation – – (305) (297) (206) (182) Net carrying amount 65 36 1,979 1,522 460 415 Movement Net carrying amount at the start of the year 36 40 1,522 711 415 389 Transfers – – 502 879 79 56 Additions14 – – 10 2 1 1 Acquisition of CSL Vifor (Note 2) 42 – 48 – 3 – Disposals (13) (4) (31) (2) (9) – Depreciation for the year – – (61) (51) (30) (27) Impairment for the year – – – – – – Currency translation differences – – (11) (17) 1 (4) Net carrying amount at the end of the year 65 36 1,979 1,522 460 415 Property, plant and equipment Land, buildings, capital work in progress and plant and equipment assets are recorded at historical cost less, where applicable, depreciation. Right-of-use assets are measured at cost, less accumulated depreciation, impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities and restoration obligations recognised less any lease incentives received and initial direct costs. Depreciation is recognised on a systematic basis over the estimated useful life of the asset, generally on a straight-line basis. Buildings 5 – 50 years Plant and equipment 3 – 40 years Leasehold improvements 3 – 25 years Right-of-use assets – Plasma centres 5 – 40 years – Office and warehouses 1 – 39 years – Land 40 – 101 years The unit-of-production depreciation method, based on the expected use or output as the asset is being used, may be applied during the early stages of operation of manufacturing facilities, as a substantial period of time may be required to ramp up the production and operate at intended capacity. This method is to be applied consistently from period to period unless there is a change in the expected pattern of consumption of those future economic benefits. Assets’ residual values and useful lives are reviewed and adjusted if appropriate at each reporting date. Items of property, plant and equipment are derecognised upon disposal or when no further economic benefits are expected from their use or disposal. Impairment testing for property, plant and equipment will be performed if an impairment trigger is identified. Gains and losses on disposals of items of property, plant and equipment are determined by comparing proceeds with carrying amounts and are included in the statement of comprehensive income when realised. Leasehold improvements The cost of improvements to leasehold properties is amortised over the unexpired period of the lease or the estimated useful life of the improvement, whichever is the shorter. CSL Limited Annual Report 2022/23 136
RkJQdWJsaXNoZXIy MjE2NDg3